4475-24-5 Usage
Description
Eprosartan related compound C is a chemical compound that is structurally related to eprosartan, an angiotensin II receptor antagonist. It is likely to share similar pharmacological and biological properties with eprosartan, potentially acting by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict.
Used in Pharmaceutical Industry:
Eprosartan related compound C is used as a potential therapeutic agent for the treatment of conditions such as hypertension and heart failure. It functions by helping to lower blood pressure and reduce the strain on the heart, similar to eprosartan.
Further research is needed to fully understand the potential therapeutic uses and mechanisms of action of eprosartan related compound C.
Check Digit Verification of cas no
The CAS Registry Mumber 4475-24-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,4,7 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 4475-24:
(6*4)+(5*4)+(4*7)+(3*5)+(2*2)+(1*4)=95
95 % 10 = 5
So 4475-24-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H8O4S/c9-7(10)6(8(11)12)4-5-2-1-3-13-5/h1-3,6H,4H2,(H,9,10)(H,11,12)
4475-24-5Relevant articles and documents
-
Owen,Nord
, p. 988,992 (1950)
-
PHOSPHINIC ACID DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY
-
, (2008/06/13)
Compounds of formula (I) wherein R, R1, R2, R3, R4 and n have the meanings reported in the description are described. The compounds of formula I are endowed with a dual ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.
N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
-
, (2008/06/13)
Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
